LabGenius, a pioneering biopharmaceutical company, has successfully raised an impressive $35 million in its latest funding round, highlighting the growing interest and confidence in innovative approaches to drug development. As the first company to harness a machine learning-driven evolution engine, known as EVAâ„¢, LabGenius is at the forefront of creating next-generation protein therapeutics. This substantial investment will enable the company to expand its revolutionary protein engineering platform, which integrates cutting-edge technologies from machine learning, synthetic biology, and robotics. By leveraging the power of EVAâ„¢, LabGenius aims to accelerate the discovery and optimization of protein-based therapeutics, promising to deliver more effective treatments for a variety of diseases that currently have limited options. The funds will be allocated toward enhancing their research capabilities, scaling up their operations, and advancing their pipeline of innovative therapies. This funding marks a significant milestone in LabGenius's mission to transform the landscape of biopharmaceuticals, ensuring that humanity can benefit from the robust capabilities of protein therapeutics enhanced through advanced technology. As LabGenius continues its journey, this new infusion of capital stands as a testament to their commitment to pushing the boundaries of science and delivering groundbreaking solutions that could significantly improve patient outcomes worldwide. The future looks bright for LabGenius as they embark on this next chapter of growth and innovation in the biopharmaceutical sector.
LabGenius Secures $35 Million in Series B Funding for Groundbreaking Protein Therapeutics Platform
Recently funded · £35.0M Series bBiotechnology Research
Get the full LabGenius company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
